Lexaria Bioscience

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. Its products can be used with APIs encompassing fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) pain medications, hormones, phosphodiesterase inhibitors, antivirals, nicotine and its analogs, and all cannabinoids including tetrahydrocannabinol (THC) for therapeutic indications, as well as hypertension, SARS-CoV-2/COVID-19, and HIV/AIDS. It operates through the following segments: IP Licensing, B2B Product, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. It operates through the following segments: IP Licensing, B2B Product, Research and Development, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

All objectives evaluating DehydraTECH ™ drug delivery platform successfully achieved KELOWNA, BC / ACCESSWIRE / July 22, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to review its successful 2021 antiviral drug program to date and summarize expected next steps. Lexaria's objectives in its 2021 antiviral drug examination program thus far have been to determine whether: DehydraTECH processing of compounds from leading classes of antiviral drugs for SARS-CoV-2/COVID-19, HIV/AIDS and other infectious diseases could exhibit evidence of superior oral absorption relative to controls, DehydraTECH processing of those compounds would preserve expected viral inhibitory performance upon efficacy testing in infected mammalian cells, and DehydraTECH does not alter nor degrade the drug molecules chemically as to create new molecular entities that could be challenging to guide through the regulatory approval process.

Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy

Lexaria Bioscience Corp. (NASDAQ:LEXX) shares are trading higher after the company announced its DehydraTECH significantly enhances delivery of colchicine in study VIRAL-A20-3. This study demonstrated that DehydraTECHTM enabled colchicine, the latest of several drugs Lexaria has successfully tested with known SARS-CoV-2 antiviral properties, said in the company's press release.

Why Lexaria Bioscience Is Surging Today

The stock price of Lexaria Bioscience Corp (NASDAQ: LEXX) increased by over 35% pre-market. This is why it happened.

LEXX Stock Increases Over 35% Pre-Market: Why It Happened

Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects KELOWNA, BC / ACCESSWIRE / July 21, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. This study demonstrated that DehydraTECHTM enabled colchicine, the latest of several drugs Lexaria has successfully tested with known SARS-CoV-2 antiviral properties, benefited from our proprietary formulation and processing, resulting in increased delivery: Drug Cmax* % Improvement (ng/mL) Control (ng/mL) AUClast** % Improvement (hr∙ng/mL) Control (hr∙ng/mL) Colchicine 31.97 91% (p=0.0005) 16.73 104.43 167% (p=0.0028) 38.97 Colchicine is an approved therapeutic with anti-inflammatory effects that is principally used to treat gout and conditions such as cardiac inflammation (i.e.

Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3

Lexaria Bioscience Corp (NASDAQ: LEXX) has announced results from its antiviral drug molecular characterization study VIRAL-MC21-1, completed by Canada's federally funded research organization, the National Research Council (NRC). The NRC has confirmed Lexaria's study objectives, demonstrating DehydraTECH processing and formulation technology does not create a covalently bonded new molecular entity.

Lexaria Shares Are Trading Higher On Completion Of Antiviral Drug Molecular Characterization Study

VIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral Drugs KELOWNA, BC / ACCESSWIRE / July 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce results from its antiviral drug molecular characterization study VIRAL-MC21-1 recently completed by Canada's premier federally funded research organization, the National Research Council ("NRC"). The NRC has successfully confirmed Lexaria's study objectives, demonstrating DehydraTECH™ processing and formulation technology does not create a covalently bonded new molecular entity ("NME") and that each drug tested remained stable and did not undergo change in chemical structure.

Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council

New patent granted in Japan adds to existing patents in the EU, the U.S., India and Australia KELOWNA, BC / ACCESSWIRE / July 13, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces an additional expansion of its intellectual property portfolio with its first-ever patent granted in Japan. The patent is titled "Stable ready-to-drink beverage compositions comprising lipophilic active agents" and becomes the 20th patent granted to Lexaria, continuing to add to the Company's considerable intellectual property portfolio.

Lexaria Receives Patent Protection in Japan

KELOWNA, BC / ACCESSWIRE / July 5, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that on June 30, 2021 it made a request to voluntarily delist its common shares from the Canadian Securities Exchange (the “CSE”). It is expected that the close of business on Wednesday, July 7, 2021 will be the final trading day for Lexaria on the CSE.

Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets

KELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the 2021 Annual Meeting (the 'Meeting'). On June 28, 2021 at 1:00 p.m.

Lexaria Announces 2021 Annual Meeting Results

New York, New York--(Newsfile Corp. - June 17, 2021) - PCG Digital -- Lexaria Bioscience Corp. (NASDAQ: LEXX) hit a major milestone this week with their patented DehydraTECHTM technology. An IC50 in vitro study was completed with COVID-19 SARS-CoV-2 antivirals Remdesivir and Ebastine and concluded that their formulation and processing methodology "did not negate the known efficacy of those compounds." "This test is conducted as a pass/fail," said Chris Bunka, CEO of Lexaria Bioscience....

Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)

DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 KELOWNA, BC / ACCESSWIRE / June 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce positive results from its tolerability and pharmacokinetic ("PK") animal study VIRAL-A20-2, evaluating DehydraTECH-enabled remdesivir and ebastine. These findings build upon Lexaria's recent announcement that remdesivir and ebastine processed with DehydraTECH were effective at inhibiting the COVID-19 SARS-CoV-2 virus using an in vitro screening assay in infected cells in its study VIRAL-C21-3.

Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs

All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine These studies are part of Lexaria's 2021 applied R&D program intended to enable opportunities for strategic partnerships KELOWNA, BC / ACCESSWIRE / June 9, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this progress report on several studies within its 2021 applied research and development (R&D) program. Other studies actively underway and planned will be reported on separately.

Lexaria Provides Progress Report on Six R&D Programs

Dosing Is Complete in First of Three Human Clinical Studies Hoped To Validate Lexaria's Patented Technology for Hypertension Relief Study Tested an Advanced “DehydraTECH™ 2.0” CBD Formulation Second Human Clinical Study, Hyper-H21-2, To Commence Immediately KELOWNA, BC / ACCESSWIRE / June 7, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to report that treatment and dosing in its human clinical study (HYPER-H21-1) have been completed ahead of schedule. HYPER-H21-1 focused on testing DehydraTECH-enabled cannabidiol ("CBD") for potential use as a hypertension treatment alternative.

Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1

Lexaria Bioscience Corp. (NASDAQ: LEXX) C hairman and CEO Chris Bunka began the Benzinga Global Small Cap Business Conference presentation on May 13, 2021, by clarifying a few key details about the company. He explained Lexaria is a drug delivery technology company — not a cannabis, psychedelics or drug company.

Lexaria Bioscience on Drug Delivery Technology and its Patented DehydraTECH

KELOWNA, BC / ACCESSWIRE / June 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that remdesivir and ebastine processed with DehydraTECH were effective at inhibiting the COVID-19 SARS-CoV-2 virus using an in vitro screening assay in infected cells in Lexaria study VIRAL-C21-3. "The main purpose of the study was to confirm that Lexaria's DehydraTECH formulation and processing methodology did not negate the known antiviral efficacy of these compounds before proceeding to larger, planned in vivo efficacy testing, said Chris Bunka, CEO of Lexaria Bioscience Corp. "These preliminary findings evidenced SARS-CoV-2 inhibitory performance commensurate with our expectations warranting ongoing and further investigation in animal testing.

Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus

Developing a safe and effective drug is important, but it's only part of the picture. For the therapeutic effect of a drug to be effective, it largely depends on the delivery system.

Lexaria's DehydraTECHTM Drug Delivery Technology Is Investigating Applications in Multiple Markets Valued Over USD $100 Billion

The stock price of Lexaria Bioscience Corp (NASDAQ: LEXX) increased by over 9% pre-market. This is why it happened.

Lexaria Bioscience (LEXX) Stock: Over 9% Increase Pre-Market Explanation

New formulation delivers up to 2,708% more CBD into bloodstream* Human clinical hypertension study HYPER-H21-1 also progressing KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce successful test results of two new "DehydraTECH™ 2.0" cannabidiol ("CBD") formulations in its second 2021 applied research and development study program, HYPER-A21-2. "One of our latest DehydraTECH 2.0 formulations gave us the strongest absorption enhancement results we've ever recorded, at 2,708% more CBD into bloodstream during the study period than the representative industry standard MCT control formulation.

Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever

New patent granted in India bolsters worldwide patent coverage, adding to existing patents in the EU, the U.S., and Australia KELOWNA, BC / ACCESSWIRE / May 12, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces further expansion of its intellectual property portfolio with its first-ever patent granted in India. The patent is titled "Stable ready-to-drink beverage compositions comprising lipophilic active agents" and is of particular importance given the size of the Indian population, which is nearly four times as large as the U.S. population.

Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted

Phoenix, Arizona--(Newsfile Corp. - May 7, 2021) - The Stock Day Podcast welcomed Lexaria Bioscience Corp. (NASDAQ: LEXX) ("the Company"), a company with a proprietary drug delivery technology, DehydraTECH™, which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream. CEO of the Company, Chris Bunka, joined Stock Day host Everett Jolly.Jolly began the interview by commenting on a recent press release detailing the Company's involvement in the hypertension market. "What are your thoughts about...

Lexaria Bioscience Corp. Discusses Potential of DehydraTECH(TM) CBD for Revolutionary Hypertension Solution with The Stock Day Podcast

Up to 2,178% more CBD delivered into bloodstream* Up to 1,737% more CBD delivered into brain tissue* KELOWNA, BC / ACCESSWIRE / May 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce successful outcomes in its first sets of data from its 2021 applied research and development (R&D) study programs. Study HYPER-A21-1 included three new "DehydraTECH 2.0" formulation variations designed to enable cannabidiol ("CBD") delivery performance enhancements and pharmacokinetic optimization.

Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1

Vancouver, British Columbia--(Newsfile Corp. - April 27, 2021) - Lexaria Bioscience Corp. (CSE: LXX) (NASDAQ: LEXX) - Chris Bunka, CEO and Chairman of Lexaria Bioscience, speaks about the Company's proprietary drug delivery technology, DehydraTECH™.If you cannot view the video above, please visit:https://b-tv.com/lexaria-bioscience-proprietary-drug-delivery-technology-ceo-clip-90sec/Lexaria Bioscience is being featured on BNN Bloomber

Lexaria Bioscience Corp., Proprietary Drug Delivery Technology, CEO Clip Video

Lexaria, listed on the NASDAQ last January, brings its powerful DehydraTech product to the CBD market. The company is undergoing research on the benefits of CBD on hypertension.

Lexaria's Dehydration Technology Makes CBD Treatment More Efficient

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) revealed that its first human clinical trial assessing its DehydraTECH CBD technology to treat high blood pressure - HYPER-H21-1 - is now officially underway.  It is the first of three clinical trials aimed at assessing this potential treatment, and dosing of human volunteers has begun, the company told investors.

Lexaria Bioscience says dosing in first human trial of DehydraTECH CBD to treat high blood pressure has started

Study to examine DehydraTECHTM CBD's ability to control blood pressure First of three human clinical studies hoped to validate Lexaria's patented technology for hypertension relief KELOWNA, BC / ACCESSWIRE / April 22, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that its human clinical hypertension study HYPER-H21-1 is officially underway. Lexaria's patented DehydraTECH CBD formulation will be examined to assess its ability to control blood pressure and assess impact on inflammation.

News for Lexaria Bioscience Stock (LEXX)